Talquetamab Steps Forward: MonumenTAL-3 - A New Potential for GPRC5D Therapy in Myeloma | EHA 2026

Talquetamab Steps Forward: MonumenTAL-3 - A New Potential for GPRC5D Therapy in Myeloma | EHA 2026
CAR-T Without the Wait: Reprogramming T-cells Inside Your Body for Myeloma | EHA 2026
Next Generation of CAR-T: AZD0120 Dual BCMA/CD19 CAR-T w/ Rapid Manufacturing for Myeloma | EHA 2026
Next Generation of CAR-T: AZD0120 Dual BCMA/CD19 CAR-T w/ Rapid Manufacturing for Myeloma | EHA 2026
Beyond MRD Negative: FORTE Trial Reveals Why Staying MRD Negative Matters in Myeloma | ASCO 2026
Duffy Null & High-Risk Myeloma in Black Patients: Insights from CoMMpass & HORIZON Study | EHA 2026
Is Autologous Stem Cell Transplant Still Standard of Care in Myeloma? New Data from EHA 2026
Arlocabtagene Autoleucel (Arlo-Cel): Promising GPRC5D CAR-T Results in Relapsed Myeloma | EHA 2026
CAR-T vs Bispecifics — Which Performs Better in Myeloma After Initial BCMA Therapy Fails? | #EHA2026
A New Way to Deliver Isatuximab in Myeloma: Safety Insights on the On-Body Injector (OBI) | #EHA2026
BMS-986453 : A Next-Generation Dual-Target CAR-T Attacking BCMA + GPRC5D in Myeloma | #EHA2026
MajesTEC-4 / EMN30 Trial: Is Teclistamab the Future of Myeloma Maintenance After Transplant? | EHA26
Understanding Clinical Trials and the Financial Side of Clinical Trials
Why is diversity and inclusion important in clinical trials?
LINKER-MM1: Linvoseltamab Shows Promise Across High-Risk Myeloma | EHA 2026
Beyond CRS & ICANS: Insights Into Delayed Neurotoxicity After BCMA CAR-T Therapy in Myeloma | #EHA26
Can Taste Loss Be Managed? TALISMAN Study Shares New Answers for Talquetamab Patients | EHA 2026